Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ppp-VEGF
- Development stage
- Preclinical
- Lead developer
- Sichuan University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ppp-VEGF is an experimental, multifunctional short interfering RNA (siRNA) molecule designed to treat cancer by simultaneously targeting multiple pathways. It consists of an siRNA sequence specific for Vascular Endothelial Growth Factor (VEGF) modified with a 5'-triphosphate (ppp) moiety. This design enables a triple mechanism of action: first, it silences VEGF expression to inhibit tumor angiogenesis; second, the 5'-triphosphate group acts as a ligand for the cytosolic pattern recognition receptor RIG-I (Retinoic acid-inducible gene I), which triggers an innate immune response and activates antitumor immunity; and third, it directly induces apoptosis in tumor cells. Preclinical studies in murine lung cancer models have demonstrated that ppp-VEGF can effectively suppress tumor growth and overcome the limitations of traditional antiangiogenic agents by combining gene silencing with immunostimulatory activity.
- Other names
- 5'-triphosphate siRNA targeting VEGF5'-triphosphate-modified siRNA targeting VEGF
02
Targets
Beyond the preview
Go deeper on ppp-VEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ppp-VEGF.